Platelet Rich Plasma (PRP)

Russell M. Nord, MD
Washington Township Medical Foundation
Fremont, CA
California Orthopaedic Association
2011 Meeting
Conflict of Interest

- I have no conflicts of interest relevant to this lecture...but there is a disclaimer.
- Few solid conclusions
- Introduction
- Background
- State of the art
“This attention in print and electronic media has resulted in the dissemination of much misinformation and has elevated patient expectations to often unrealistic levels. As orthopaedic surgeons, we are ultimately responsible for interpreting the science, determining the appropriate indications, and counseling our patients about what PRP can and cannot accomplish.”

S. Terry Canale, MD and Frank B. Kelly, MD
Outline

- Definition of PRP
  - Proposed mechanism of action
  - Preparation technique
  - Available preparations

- History of Use
  - Now used for almost anything
  - Safe, inexpensive, autologous

- Known Efficacy Data

- Coding

- Future Directions and Predictions
What is PRP?

- Platelet-concentrated aliquot
- 3-5x normal blood platelet concentration
- Growth factor concentrate - mixture of growth factors
- +/- WBCs
- “Enhances healing”

**TABLE 1**

Factors Identified Within Platelet-Rich Plasma and Their Physiologic Effect

<table>
<thead>
<tr>
<th>Factor</th>
<th>Target Cell/Tissue</th>
<th>Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>PD-EGF</td>
<td>Blood vessel cells, outer skin cells, fibroblasts, and many other cell types</td>
<td>Cell growth, recruitment, differentiation, skin closure, cytokine secretion</td>
</tr>
<tr>
<td>PDGF A + B</td>
<td>Fibroblasts, smooth muscle cells, chondrocytes, osteoblasts, mesenchymal stem cells</td>
<td>Potential cell growth, recruitment, blood vessel growth, granulation</td>
</tr>
<tr>
<td>TGF-β1</td>
<td>Blood vessel tissue, outer skin cells, fibroblasts, monocytes</td>
<td>Blood vessel (±), collagen synthesis, growth inhibition, apoptosis (cell death), differentiation, activation</td>
</tr>
<tr>
<td>IGF-I, II</td>
<td>Bone, blood vessel, skin, other tissues, fibroblasts</td>
<td>Cell growth, differentiation, recruitment, collagen synthesis with PDGF</td>
</tr>
<tr>
<td>VEGF, ECGF</td>
<td>Blood vessel cells</td>
<td>Cell growth, migration, new blood vessel growth, anti-apoptosis (anti–cell death)</td>
</tr>
<tr>
<td>bFGF</td>
<td>Blood vessels, smooth muscle, skin, fibroblasts, other cell types</td>
<td>Cell migration, blood vessel growth</td>
</tr>
</tbody>
</table>
How is PRP Administered?

- Autologous, sterile blood draw
  - Variable volume
  - ? Anesthesiologist
  - 18 gauge needle
  - Reduce platelet trauma and activation

- Anticoagulation

- Centrifugation
  - Variable durations
  - Variable number of cycles

- Sequestration of PRP
  - Syringe system

+/- Activation with CaCl₂ or thrombin
- Rapid degranulation

Application / injection of PRP at desired anatomic site
- Many uses
- ? Local anesthetic
  - pH changes

Post injection
- Observe for 20 mins for pain
- ? Avoidance of NSAIDs for 3-4 weeks post-tx (prostaglandins)
- Ice
- Acetaminophen

Local anesthetic
- pH changes

Post injection
- Observe for 20 mins for pain
- ? Avoidance of NSAIDs for 3-4 weeks post-tx (prostaglandins)
- Ice
- Acetaminophen
**PRP Variability**

- 15-20 companies making PRP products
- Patient variability
- Heterogeneous PRP formulations

### Table 2

<table>
<thead>
<tr>
<th>System</th>
<th>Volume of Blood (mL)</th>
<th>Centrifuge Time/Speed</th>
<th>Final PRP Volume (mL)</th>
<th>Final Platelet Concentration (compared with average)</th>
<th>Activator</th>
<th>Level of Growth Factors (compared with average)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Autologous Conditioned Plasma (Arthrex, Naples, FL)</td>
<td>9</td>
<td>5 min/1,500 rpm</td>
<td>3-5</td>
<td>2-3x</td>
<td>None</td>
<td>PDGF (25x)</td>
</tr>
<tr>
<td>Cascade (Musculoskeletal Tissue Foundation, Edison, NJ)</td>
<td>9 or 18</td>
<td>First: 6 min/1,100g; Second: 15 min/1,450g</td>
<td>2 or 4</td>
<td>N/A</td>
<td>Calcium (forms a sutureable clot for intraoperative use)</td>
<td>PDGF (N/A)</td>
</tr>
<tr>
<td>GPS III (Biomet, Warsaw, IN)</td>
<td>27 or 54</td>
<td>15 min/1,900g</td>
<td>3 or 6</td>
<td>4-8x</td>
<td>Calcium chloride/thrombin</td>
<td>PDGF (N/A)</td>
</tr>
<tr>
<td>SmartPReP (Harvest Technologies, Plymouth, MA)</td>
<td>20 or 60</td>
<td>14 min/1,000g</td>
<td>3 or 7</td>
<td>4.4-7.6x</td>
<td>Thrombin</td>
<td>PDGF (4.4x)</td>
</tr>
</tbody>
</table>

Note: Data from manufacturers. Dragoo et al. AJSM. 2011. - 3rd party data, 3 preps.
History

• Began in late 1990’s
  • Non-orthopedic literature
    • Dental / Maxillofacial
      • Bone Graft enhancement
      • Marx et al. 1998.
    • Plastic surgical literature
      • Improved cosmetic surgery recovery
  • Orthopaedic literature
    • Augmentation of spinal fusion and fracture healing

The New York Times

February 17, 2009

A Promising Treatment for Athletes, in Blood
High Profile Patients

- Allowed
  - NFL
  - MLB
  - NBA
  - WADA
  - IOC
Proposed Non-Orthopaedic Uses

- Cosmetic Blepharoplasty
- Treatment of male pattern baldness
- Plenty more...
Science or Enthusiasm?

- Treats previously untreatable condition
  - Tendinopathy
- Potential utility in a broad spectrum of pathologies
- Limited efficacy data
- Inexpensive
- Safe
  - Autologous
  - WBCs in joint
  - Standard contraindications
- We must acknowledge our knowledge gaps...or else.
Outcomes Data - Non-Operative

- Achilles tendinopathy -
    - Double blind, placebo controlled, randomized, 54 patients, No benefit at 6 mos.

- Acute Achilles tendon injury
  - Virchenko and Aspenberg. 2006.
    - Greater initial tendon strength in rat model at 14 days when exposed to mechanical loading.

- Lateral epicondylitis
    - RCT, 100 patients
      - Goal: 25% VAS or DASH reduction at 1 year
      - 73% with PRP
      - 50% with corticosteroid

- Patellar tendinitis
    - Uncontrolled, 3 weekly injections. 20 patients. 80% satisfied at 6 mos.

- Muscle injuries
  - Sanchez et al. 2005. Poster
    - 20 patients. Recovered in half the “expected” time.
    - Improved mechanical testing in rat model

- Plantar fasciitis
    - 6/9 patients w/ complete relief at 2 mos

- Knee osteoarthritis / cartilage degen
    - 3 weekly injections. 100 pts, 1 year f/u
    - Scores improved throughout (IKDC, VAS)
      - Best in young w/ low deg of degen
      - Drop somewhat after 6 mos
    - RCT underway with HA
      - Prelim: similar, painful PRP injection

- Grade 2 MCL Injuries
    - 27% reduction in return to play time.
Outcomes Data - Operative

- **Rotator cuff repair**
  - Randomized, controlled - 87 patients total
  - No difference at 16 months
  - Randelli et al., 2011
  - Randomized, controlled - 53 patients total
  - No difference at 6, 12 or 24 months

- **Achilles tendon repair**
  - Schepull et al. 2011.
  - Randomized, controlled, prospective, single-blinded trial
    - 16 with PRP, 14 controls, 1 year f/u
    - No differences, possibly lower Achilles Tendon Total Rupture Score with PRP
    - 6 cases, 6 controls, PRP patients with earlier functional ROM, jogging, training, smaller cross-section and no wound complications.

- **ACL**
  - No studies to strongly support use
    - Graft homogeneity on MRI at 6 months instead of 1 year

- **Cartilage restoration**
  - Gobbi, 2009 presentation
    - 20 patients, PRP with collagen membrane. At 20 months, improved IKDC and Lysholm scores and near-pre-injury Tegner scores and hyaline like tissue on pathology.
    - Rabbit model - PRP in PLGA scaffold helps heal osteochondral defects

- **Total Knee Arthroplasty**
    - 71 experimental, 66 controls. PRP in tissue prior to closure. Less blood loss, shorter hospital stay, 5 deg more ROM at 6 wks with PRP.

- **Spinal Fusion**
    - Clinical study: No improvement in fusion rate
    - No improvements in rat model

- **Femur Fractures**
    - Accelerated bone healing in rat femurs
Future Directions

- Improved high-level prospective studies
- Define and classify types of PRP
- Elucidate which works best in what setting

**Prediction:** Isolated high-quality studies on specific proprietary formulations used for a discrete pathology will yield outcome data that cannot be extrapolated to other formulations or pathologies.

- “Islands of data”
Conclusions

- Identify low-morbidity applications
  - Appropriate for use with limited data
- Appropriate disclosure to patients
- 0232T code
  - Often not covered
  - Out-of-pocket expenses
- Follow the developments in the literature
- Best Review Paper
  - AAOS Now PDF